Corvus Pharmaceuticals, Inc

(NASDAQ:CRVS)

Latest On Corvus Pharmaceuticals, Inc (CRVS):

Date/Time Type Description Signal Details
2023-05-12 22:21 ESTNewsCorvus Pharmaceuticals: Targeting $1 Billion/Year U.S. T-Cell Lymphoma MarketN/A
2023-05-08 22:39 ESTNewsCorvus Pharmaceuticals GAAP EPS of -$0.17 misses by $0.01N/A
2023-05-08 22:39 ESTNewsCorvus Pharmaceuticals, Inc. (CRVS) Q1 2023 Earnings Call TranscriptN/A
2023-05-07 20:51 ESTNewsCorvus Pharmaceuticals Q1 2023 Earnings PreviewN/A
2023-03-29 11:09 ESTNewsCorvus Pharmaceuticals, Inc. (CRVS) Q4 2022 Earnings Call TranscriptN/A
2023-03-28 20:35 ESTNewsCorvus Pharmaceuticals GAAP EPS of -$0.21 beats by $0.02N/A
2022-11-07 01:12 ESTNewsCorvus Pharmaceuticals, Inc. (CRVS) Q3 2022 Earnings Call TranscriptN/A
2022-11-04 01:21 ESTNewsCorvus Pharmaceuticals GAAP EPS of -$0.32 misses by $0.16N/A
2022-11-03 07:35 ESTNewsCorvus Pharmaceuticals Q3 2022 Earnings PreviewN/A
2022-09-26 18:13 ESTNewsCorvus' partner Angel Pharma gets nod to start phase 1/1b trial of cancer therapy in ChinaN/A
2022-08-09 00:57 ESTNewsCorvus Pharmaceuticals GAAP EPS of -$0.18 in-lineN/A
2022-08-09 00:56 ESTNewsCorvus Pharmaceuticals, Inc. (CRVS) CEO Richard Miller on Q2 2022 Results - Earnings Call TranscriptN/A
2022-08-06 08:07 ESTNewsCorvus Pharmaceuticals Q2 2022 Earnings PreviewN/A
2022-05-06 01:39 ESTNewsCorvus Pharmaceuticals GAAP EPS of -$0.18N/A
2022-03-11 09:34 ESTNewsCorvus Pharmaceuticals GAAP EPS of -$0.20 misses by $0.01N/A
2022-03-11 09:34 ESTNewsCorvus Pharmaceuticals, Inc. (CRVS) CEO Richard Miller on Q4 2021 Results - Earnings Call TranscriptN/A
2022-03-09 22:06 ESTNewsCorvus Pharmaceuticals Q4 2021 Earnings PreviewN/A
2022-01-14 06:28 ESTNewsCorvus Pharma initiates Phase 1/1b trial of CPI-818 for T-cell lymphomas in ChinaN/A
2021-12-11 08:34 ESTNewsChecking In On Corvus PharmaceuticalsN/A
2021-11-01 17:42 ESTNewsCorvus Pharmaceuticals EPS misses by $0.03N/A
2021-09-24 02:10 ESTNewsCorvus Pharmaceuticals: More Than A CD73 Sympathy PlayN/A
2021-09-23 00:42 ESTNewsCorvus: Surging On AstraZeneca CD73 Success With Key Data Readout LoomingN/A
2021-09-21 15:24 ESTNewsAstraZeneca lung cancer data propel Corvus and ArcusN/A
2021-09-21 15:23 ESTNewsCRVS, APRE, GDS and OYST among after hours moversN/A
2021-09-21 15:23 ESTNewsCorvus Pharma has stellar day closing 135% higher; reaches 52-week high after-hoursN/A
2021-09-21 15:20 ESTNewsAPRE, GMAB, VRCA and CRVS among after hours moversN/A
2021-09-21 15:18 ESTNewsCorvus Pharma extends gains to more than double in value this yearN/A
2021-08-17 11:34 ESTNewsCorvus Pharma to commence Phase 1/1b trial of CPI-818 in ChinaN/A
2021-08-03 09:45 ESTNewsCorvus Pharmaceuticals EPS in-lineN/A
2021-07-21 03:20 ESTNewsCorvus Pharmaceuticals initiated buy at Cantor with a Street-high targetN/A
2021-07-21 02:29 ESTNewsCorvus shares drop after scrapping late-stage mupadolimab COVID-19 trialN/A
2021-07-21 02:28 ESTNewsCorvus Pharma praised for its focus after end to COVID-19 studyN/A
2021-03-25 12:00 ESTNewsCorvus Pharmaceuticals EPS beats by $1.16N/A
2021-03-12 22:57 ESTNewsCorvus Pharmaceuticals (CRVS) Investor Presentation - SlideshowN/A
2021-02-23 03:28 ESTAnalyst RatingThe Analyst Target Price has increased from $8.6 to $9.25.Buy
2021-02-20 01:27 ESTNewsCorvus Pharma surges after an insider purchase of ~1.3M sharesN/A
2021-02-17 19:28 ESTNewsCorvus closes 8.6M share public offeringN/A
2021-02-12 16:58 ESTNewsCorvus shares slide after pricing 8.57M public offeringN/A
2021-02-11 23:25 ESTNewsCorvus Pharma announces proposed public offeringN/A
2021-02-11 11:23 ESTAnalyst RatingThe Analyst Target Price has decreased from $9.2 to $8.6.Neutral
2021-02-11 05:12 ESTNewsCorvus cut to neutral at Mizuho citing realignment of pipelineN/A
2021-01-20 16:29 ESTNewsCorvus Pharmaceuticals: Undervalued Based On COVID-19 Opportunity And Oncology AssetsN/A
2020-12-13 03:43 ESTFinancialsCompany financials have been released.Neutral
2020-11-10 10:46 ESTNewsCorvus' immunotherapy shows durable benefit in COVID-19N/A
2020-11-07 15:30 ESTFinancialsCompany financials have been released.Neutral
2020-11-07 06:14 ESTNewsSeeking Alpha Catalyst WatchN/A
2020-11-02 17:03 ESTAnalyst RatingThe Analyst Target Price has decreased from $9.6 to $9.2.Neutral
2020-11-01 23:28 ESTFinancialsCompany financials have been released.Neutral
2020-10-30 20:36 ESTEarnings EstimateAn EPS average of -$0.33 is estimated for the quarter ending on March 31, 2021.N/A
2020-10-07 16:40 ESTAnalyst RatingThe Analyst Target Price has increased from $9.2 to $9.6.Buy

About Corvus Pharmaceuticals, Inc (CRVS):

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase Ib/2 clinical trial for adenosine, an immune checkpoint. The company is also developing CPI-006, an anti-CD73 monoclonal antibody, which is in Phase I/Ib clinical trial that inhibits the production of adenosine and stimulate various immune cells, as well as Phase I clinical trial of CPI-006 for COVID-19; an antagonist of the adenosine A2B receptor; and CPI-818, a small molecule covalent inhibitor of interleukin-2-inducible T-cell kinase, that is Phase I/Ib clinical trial. Corvus Pharmaceuticals, Inc. also entered into a strategic collaboration with Angel Pharmaceuticals for the development its pipeline of targeted investigational medicines. The company was founded in 2014 and is based in Burlingame, California.

CRVS Quotes by TradingView

See Advanced Chart

General

  • Name Corvus Pharmaceuticals, Inc
  • Symbol CRVS
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 52
  • Fiscal Year EndDecember
  • IPO Date2016-03-23
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Gic SubIndustryBiotechnology
  • Web URLhttp://www.corvuspharma.com
View More

Valuation

  • Price/Book (Most Recent Quarter) 2.95
  • Enterprise Value EBITDA 0.14
View More

Financials

  • Most Recent Quarter 2020-09-30
  • Next Quarter EPS Estimate -$0.23
  • Return on Assets -38%
  • Return on Equity -72%
  • Earnings Per Share -$1.56
  • Revenue Per Share $0
  • Quarterly Earnings Growth 0%
View More

Highlights

  • Market Capitalization 120.35 million
  • EBITDA -47441000
  • Analyst Target Price $9.25
  • Book Value Per Share $1.51
View More

Share Statistics

  • Shares Outstanding 37.85 million
  • Shares Float 17.12 million
  • % Held by Insiders 498%
  • % Held by Institutions 63.75%
  • Shares Short 1.27 million
  • Shares Short Prior Month 1.24 million
  • Short Ratio 0.76
  • Short % of Float 5%
  • Short % of Shares Outstanding 3%
View More

Technicals

  • Beta 1.77
  • 52 Week High $5.28
  • 52 Week Low $1.91
  • 50 Day Moving Average 3.63
  • 200 Day Moving Average 3.89
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Corvus Pharmaceuticals, Inc (CRVS) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Corvus Pharmaceuticals, Inc (CRVS) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-09-302020-10-29$N/A-$0.33-$0.22-51.72%
2020-06-302020-07-30$N/A-$0.36-$0.24-51.58%
2020-03-312020-04-30$N/A-$0.44-$0.41-8.64%
2019-12-312020-03-05$N/A-$0.38-$0.31-22.58%
2019-09-302019-10-29$N/A-$0.37-$0.4313.29%
2019-06-302019-08-01$N/A-$0.44-$0.44-0.76%
2019-03-312019-05-09$N/A-$0.40-$0.4816.05%
2018-12-312019-03-07$N/A-$0.36-$0.5028%
2018-09-302018-11-01$N/A-$0.36-$0.4926.03%
2018-06-302018-08-02$N/A-$0.40-$0.6134.16%
2018-03-312018-05-03$N/A-$0.63-$0.7718%
2017-12-312018-03-01$N/A-$0.58-$0.7724.58%
2017-09-302017-11-02$N/A-$0.62-$0.8425.82%
2017-06-302017-08-03$N/A-$0.73-$0.741.12%
2017-03-312017-05-04$N/A-$0.79-$0.77-2.6%
2016-12-312017-03-10$N/A-$0.55-$0.55-0.73%
2016-09-302016-11-03$N/A-$0.51-$0.45-13.33%
2016-06-302016-08-04$N/A-$0.43-$0.32-36.38%
2016-03-312016-05-05$N/A-$5.39-$6.0911.49%

Corvus Pharmaceuticals, Inc (CRVS) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019 Sep 30 2019
Research Development N/A N/A N/A 8.92 million 9 million
Income Before Tax N/A N/A N/A -11.05 million -11 million
Selling General Administrative N/A N/A N/A 2.52 million 2.52 million
Gross Profit N/A N/A N/A N/A N/A
Ebit N/A N/A N/A -11.44 million -11.51 million
Operating Income N/A N/A N/A -11.44 million -11.51 million
Income Tax Expense N/A N/A N/A N/A N/A
Total Revenue N/A N/A N/A N/A N/A
Cost of Revenue N/A N/A N/A N/A N/A
Total Other Income Expense Net N/A N/A N/A 393000 509000
Net Income From Continuing Operations N/A N/A N/A -11.05 million -11 million
Net Income Applicable to Common Shares -9.8 million -10.61 million -12.94 million -11.05 million -11 million
Cash Flow:
Date Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019 Sep 30 2019
Investments N/A N/A N/A N/A -10.52 million
Change to Liabilities -208000 -577000 908000 N/A -728000
Total Cash Flow from Investing Activities 9.94 million 6.67 million 27.7 million N/A -10.53 million
Net Borrowings N/A N/A N/A N/A N/A
Total Cash Flow from Financial Activities N/A N/A N/A N/A 16000
Change to Operating Activities 730000 164000 709000 N/A -590000
Change in Cash N/A N/A N/A N/A -21.12 million
Total Cash from Operating Activities -7.73 million -9.49 million -9.35 million N/A -10.61 million
Depreciation N/A N/A N/A N/A 186000
Other Cash Flow from Investing Activities N/A N/A N/A N/A N/A
Change to Inventory N/A N/A N/A N/A N/A
Change to Account Receivables N/A N/A N/A N/A N/A
Other Cash Flow from Financing Activities N/A N/A N/A N/A N/A
Change to Net Income 1.4 million 1.38 million 1.78 million N/A 1.53 million
Capital Expenditures N/A N/A N/A N/A 4000
Balance Sheet:
Date Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019 Sep 30 2019
Total Liabailities N/A N/A N/A 12.54 million 12.06 million
Total Stockholder Equity N/A N/A N/A 71.11 million 80.41 million
Other Current Liabilities N/A N/A N/A N/A N/A
Total Assets N/A N/A N/A 83.65 million 92.47 million
Common Stock 3000 3000 3000 71.11 million 3000
Other Current Assets N/A N/A N/A N/A 683000
Retained Earnings -250.49 million -240.69 million -230.08 million N/A -206.1 million
Other Liabilities N/A N/A N/A N/A N/A
Other Assets 480000 501000 513000 3.34 million 513000
Cash N/A N/A N/A 77.98 million 9.07 million
Total Current Liabilities 12 million N/A N/A 9.35 million 9.52 million
Other Stockholder Equity 12000 53000 43000 N/A 34000
Property, Plant & Equipment 2.87 million 3.12 million 3.44 million 2.33 million 4.13 million
Total Current Assets 52.51 million N/A N/A 77.98 million 87.83 million
Long Term Investments N/A N/A N/A N/A N/A
Net Tangible Assets 42.35 million 50.84 million 60.04 million 71.11 million 80.41 million
Short Term Investments N/A N/A N/A N/A 77.35 million
Long Term Debt N/A N/A N/A N/A N/A
Inventory N/A N/A N/A N/A N/A
Accounts Payable 2.57 million N/A N/A 9.35 million 1.91 million

Corvus Pharmaceuticals, Inc (CRVS) Chart:

Corvus Pharmaceuticals, Inc (CRVS) News:

Below you will find a list of latest news for Corvus Pharmaceuticals, Inc (CRVS) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Corvus Pharmaceuticals, Inc (CRVS) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent
2025-12-1910CALL0 01416.9TRUE00
2025-12-1920CALL0 0548.41TRUE00
2025-12-1935.5CALL4 4464.68TRUE5.50
2025-12-1944.55CALL3 3385.96TRUE4.550
2025-12-1953.56CALL4 4292.94TRUE3.560
2025-12-1962.62CALL5 5234.63TRUE2.620
2025-12-1971.57CALL5 1017140.07TRUE1.570
2025-12-1980.75CALL23 12985.86TRUE0.750
2025-12-1990.22CALL3 114688.94FALSE-0.13-0.37
2025-12-19100.05CALL0 119287.68FALSE00
2025-12-19110.04CALL0 448177.43FALSE00
2025-12-19120.05CALL0 10404.71FALSE00
2025-12-19130.05CALL0 5314.67FALSE00
2025-12-19140.23CALL0 30285.55FALSE00
2025-12-19150.26CALL0 1310.07FALSE00
2025-12-1910PUT0 00FALSE00
2025-12-1920PUT0 01254.7FALSE00
2025-12-1930.15PUT0 2596.98FALSE00
2025-12-1940.22PUT0 1451.13FALSE00
2025-12-1950.15PUT0 5339.86FALSE00
2025-12-1960.25PUT0 8247.89FALSE00
2025-12-1970.1PUT0 150166.55FALSE00
2025-12-1980.19PUT11 78081.73FALSE-0.09-0.32
2025-12-1990.6PUT12 42680.28TRUE-0.05-0.08
2025-12-19101.09PUT0 19384.67TRUE00
2025-12-19112.9PUT0 10TRUE00
2025-12-19120PUT0 00TRUE00
2025-12-19130PUT0 00TRUE00
2025-12-19140PUT0 00TRUE00
2025-12-19150PUT0 00TRUE00
2026-01-1613.3CALL0 0498.79TRUE00
2026-01-1625.4CALL0 5328.42TRUE00
2026-01-1635.16CALL0 41311.32TRUE00
2026-01-1644.6CALL3 297194.76TRUE4.60
2026-01-1653.8CALL0 358156.77TRUE00
2026-01-1663CALL2 851150.07TRUE30
2026-01-1672.35CALL0 1499146.83TRUE00
2026-01-1681.75CALL10 4152150.16TRUE-0.05-0.03
2026-01-1691.32CALL159 1097147.24FALSE-0.03-0.02
2026-01-16100.97CALL121 593143.58FALSE00
2026-01-16110.8CALL0 70137.76FALSE00
2026-01-16120.52CALL110 188140.04FALSE00
2026-01-16130.35CALL0 14135.16FALSE00
2026-01-16140.35CALL0 69137.93FALSE00
2026-01-16150.16CALL0 170164.2FALSE00
2026-01-1610.21PUT0 70750.9FALSE00
2026-01-1620.05PUT0 32552.38FALSE00
2026-01-1630.05PUT0 80282.07FALSE00
2026-01-1640.11PUT0 631165.56FALSE00
2026-01-1650.25PUT0 369171.38FALSE00
2026-01-1660.4PUT0 628138.1FALSE00
2026-01-1670.75PUT0 1150143.93FALSE00
2026-01-1681.1PUT21 494140.39FALSE-0.05-0.04
2026-01-1691.55PUT0 12138.73TRUE00
2026-01-16102.2PUT0 215137.6TRUE00
2026-01-16112.8PUT0 5133.59TRUE00
2026-01-16120PUT0 0130.36TRUE00
2026-01-16130PUT0 00TRUE00
2026-01-16140PUT0 0132.13TRUE00
2026-01-16150PUT0 0124.72TRUE00
2026-04-1710CALL0 0353.1TRUE00
2026-04-1727CALL0 4123.18TRUE00
2026-04-1736.1CALL0 680TRUE00
2026-04-1744.3CALL0 22146.84TRUE00
2026-04-1754.23CALL0 117134.61TRUE00
2026-04-1763.7CALL7 1074138.49TRUE3.70
2026-04-1773.1CALL1 442129.98TRUE3.10
2026-04-1782.49CALL1 1757118.7TRUE-0.11-0.04
2026-04-1792.3CALL7 310127.63FALSE0.10.05
2026-04-17101.85CALL5 1875119.82FALSE00
2026-04-17111.67CALL0 308120.05FALSE00
2026-04-17121.45CALL0 548119.55FALSE00
2026-04-17131.43CALL0 162118.64FALSE00
2026-04-17141.08CALL0 171118.88FALSE00
2026-04-17150.95CALL0 1706116.44FALSE00
2026-04-1710PUT0 0315.05FALSE00
2026-04-1720.15PUT0 11178.16FALSE00
2026-04-1730.21PUT0 65188.7FALSE00
2026-04-1740.6PUT0 4180.59FALSE00
2026-04-1750.6PUT0 44131.16FALSE00
2026-04-1761PUT20 800122.14FALSE10
2026-04-1771.45PUT0 90122.76FALSE00
2026-04-1781.97PUT0 60121.68FALSE00
2026-04-1792.6PUT0 57119.87TRUE00
2026-04-17103.28PUT0 311120.4TRUE00
2026-04-17113.61PUT0 5118.5TRUE00
2026-04-17124.3PUT0 3119.64TRUE00
2026-04-17135.05PUT0 3119.07TRUE00
2026-04-17147.56PUT0 160116.9TRUE00
2026-04-17150PUT0 0118.93TRUE00
2026-07-1710CALL0 0268.04TRUE00
2026-07-1727.48CALL0 8149.47TRUE00
2026-07-1730CALL0 087.87TRUE00
2026-07-1740CALL0 0121.15TRUE00
2026-07-1754.7CALL0 47117.86TRUE00
2026-07-1764.1CALL0 4112.48TRUE00
2026-07-1773.1CALL0 16109.84TRUE00
2026-07-1782.9CALL0 911110.38TRUE00
2026-07-1792.77CALL1 851108.61FALSE2.770
2026-07-17102.5CALL5 562108.15FALSE0.20.09
2026-07-17112.07CALL0 246108.14FALSE00
2026-07-17121.8CALL0 254106.86FALSE00
2026-07-17131.65CALL0 78107.4FALSE00
2026-07-17140CALL0 0107FALSE00
2026-07-17150CALL0 0106.78FALSE00
2026-07-17160CALL0 0106.86FALSE00
2026-07-17171.25CALL0 40106.3FALSE00
2026-07-1710PUT0 0241.57FALSE00
2026-07-1720PUT0 0142.48FALSE00
2026-07-1730PUT0 0129.71FALSE00
2026-07-1740PUT0 0121.9FALSE00
2026-07-1750.95PUT0 40114.72FALSE00
2026-07-1761.24PUT0 2110.93FALSE00
2026-07-1771.55PUT0 4110.53FALSE00
2026-07-1782.45PUT0 10108.46FALSE00
2026-07-1792.8PUT0 8108.48TRUE00
2026-07-17103.68PUT0 12107.62TRUE00
2026-07-17110PUT0 0108.15TRUE00
2026-07-17120PUT0 0107.35TRUE00
2026-07-17130PUT0 0107.37TRUE00
2026-07-17140PUT0 0106.4TRUE00
2026-07-17150PUT0 0106.55TRUE00
2026-07-17160PUT0 0108TRUE00
2026-07-17170PUT0 0106.72TRUE00

Latest CRVS Trades:

Date Shares Price
Jun 13, 2022 7:13 PM EST45$0.9764
Jun 13, 2022 7:19 PM EST2$0.9763
Jun 13, 2022 7:20 PM EST45$0.9734
Jun 13, 2022 7:20 PM EST90$0.9733
Jun 13, 2022 7:20 PM EST100$0.9702

Corvus Pharmaceuticals, Inc (CRVS) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-06-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626971/000110465920073458/0001104659-20-073458-index.htm
2018-08-01UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1626971/000000000018023785/0000000000-18-023785-index.htm
2018-08-24UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1626971/000000000018026391/0000000000-18-026391-index.htm
2020-03-12UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1626971/000000000020002243/0000000000-20-002243-index.htm
2019-02-14SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1626971/000008025519002716/0000080255-19-002716-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1626971/000008025520001312/0000080255-20-001312-index.htm
2019-02-13SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1626971/000031506619000997/0000315066-19-000997-index.htm
2018-06-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626971/000089924318017912/0000899243-18-017912-index.htm
2018-06-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626971/000089924318017913/0000899243-18-017913-index.htm
2018-06-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626971/000089924318017914/0000899243-18-017914-index.htm
2018-06-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626971/000089924318017915/0000899243-18-017915-index.htm
2018-06-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626971/000089924318017916/0000899243-18-017916-index.htm
2018-12-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626971/000089924318030242/0000899243-18-030242-index.htm
2018-12-104Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626971/000089924318030539/0000899243-18-030539-index.htm
2018-12-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626971/000089924318031054/0000899243-18-031054-index.htm
2018-12-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626971/000089924318031055/0000899243-18-031055-index.htm
2018-12-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626971/000089924318031057/0000899243-18-031057-index.htm
2018-12-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626971/000089924318031058/0000899243-18-031058-index.htm
2018-12-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626971/000089924318031059/0000899243-18-031059-index.htm
2018-12-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626971/000089924318031061/0000899243-18-031061-index.htm
2018-12-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626971/000089924318031696/0000899243-18-031696-index.htm
2018-12-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626971/000089924318031810/0000899243-18-031810-index.htm
2018-12-314Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626971/000089924318031989/0000899243-18-031989-index.htm
2019-01-303Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626971/000089924319002186/0000899243-19-002186-index.htm
2019-01-303Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626971/000089924319002187/0000899243-19-002187-index.htm
2019-01-304Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626971/000089924319002190/0000899243-19-002190-index.htm
2019-01-304Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626971/000089924319002194/0000899243-19-002194-index.htm
2019-06-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626971/000089924319017182/0000899243-19-017182-index.htm
2019-06-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626971/000089924319017913/0000899243-19-017913-index.htm
2019-06-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626971/000089924319017914/0000899243-19-017914-index.htm
2019-06-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626971/000089924319017917/0000899243-19-017917-index.htm
2019-06-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626971/000089924319017918/0000899243-19-017918-index.htm
2019-06-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626971/000089924319017919/0000899243-19-017919-index.htm
2019-06-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626971/000089924319017924/0000899243-19-017924-index.htm
2019-08-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626971/000089924319021352/0000899243-19-021352-index.htm
2019-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1626971/000092189519000470/0000921895-19-000470-index.htm
2019-08-07SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1626971/000092189519002114/0000921895-19-002114-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1626971/000092189520000529/0000921895-20-000529-index.htm
2020-02-18SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1626971/000092189520000584/0000921895-20-000584-index.htm
2019-07-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626971/000094787119000486/0000947871-19-000486-index.htm
2019-07-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626971/000094787119000487/0000947871-19-000487-index.htm
2019-07-02SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1626971/000094787119000489/0000947871-19-000489-index.htm
2019-08-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626971/000094787119000571/0000947871-19-000571-index.htm
2019-08-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626971/000094787119000572/0000947871-19-000572-index.htm
2020-04-17SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1626971/000094787120000390/0000947871-20-000390-index.htm
2018-04-27DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1626971/000110465918027395/0001104659-18-027395-index.htm
2018-05-0310-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1626971/000110465918030262/0001104659-18-030262-index.htm
2018-08-1710-K/AAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1626971/000110465918052661/0001104659-18-052661-index.htm
2018-08-17CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1626971/000110465918052664/0001104659-18-052664-index.htm
2019-05-09S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1626971/000110465919028231/0001104659-19-028231-index.htm
2019-11-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1626971/000110465919062177/0001104659-19-062177-index.htm
2020-03-09S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1626971/000110465920030827/0001104659-20-030827-index.htm
2020-03-17CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1626971/000110465920034837/0001104659-20-034837-index.htm
2020-03-20424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1626971/000110465920036930/0001104659-20-036930-index.htm
2020-03-234Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626971/000110465920037295/0001104659-20-037295-index.htm
2020-04-30S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1626971/000110465920054482/0001104659-20-054482-index.htm
2020-06-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626971/000110465920073458/0001104659-20-073458-index.htm
2020-10-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1626971/000110465920112250/0001104659-20-112250-index.htm
2018-06-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626971/000114420418035629/0001144204-18-035629-index.htm
2019-06-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626971/000114420419032055/0001144204-19-032055-index.htm
2018-05-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1626971/000117184318003466/0001171843-18-003466-index.htm
2018-06-228-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1626971/000117184318004798/0001171843-18-004798-index.htm
2018-06-288-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1626971/000117184318004870/0001171843-18-004870-index.htm
2018-08-028-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1626971/000117184318005700/0001171843-18-005700-index.htm
2018-10-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1626971/000117184318006835/0001171843-18-006835-index.htm
2018-10-228-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1626971/000117184318007090/0001171843-18-007090-index.htm
2018-11-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1626971/000117184318007480/0001171843-18-007480-index.htm
2018-11-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1626971/000117184318007863/0001171843-18-007863-index.htm
2018-12-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1626971/000117184318008443/0001171843-18-008443-index.htm
2019-01-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1626971/000117184319000179/0001171843-19-000179-index.htm
2019-01-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1626971/000117184319000219/0001171843-19-000219-index.htm
2019-01-288-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1626971/000117184319000555/0001171843-19-000555-index.htm
2019-02-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1626971/000117184319000753/0001171843-19-000753-index.htm
2019-03-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1626971/000117184319001583/0001171843-19-001583-index.htm
2019-05-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1626971/000117184319003207/0001171843-19-003207-index.htm
2019-06-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1626971/000117184319003763/0001171843-19-003763-index.htm
2019-06-248-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1626971/000117184319004128/0001171843-19-004128-index.htm
2019-08-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1626971/000117184319005090/0001171843-19-005090-index.htm
2019-10-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1626971/000117184319006916/0001171843-19-006916-index.htm
2019-11-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1626971/000117184319007381/0001171843-19-007381-index.htm
2019-12-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1626971/000117184319008006/0001171843-19-008006-index.htm
2019-12-168-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1626971/000117184319008140/0001171843-19-008140-index.htm
2020-02-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1626971/000117184320000651/0001171843-20-000651-index.htm
2020-02-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1626971/000117184320000943/0001171843-20-000943-index.htm
2020-03-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1626971/000117184320001518/0001171843-20-001518-index.htm
2020-03-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1626971/000117184320001878/0001171843-20-001878-index.htm
2020-04-308-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1626971/000117184320003129/0001171843-20-003129-index.htm
2020-05-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1626971/000117184320004067/0001171843-20-004067-index.htm
2020-06-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1626971/000117184320004286/0001171843-20-004286-index.htm
2020-07-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1626971/000117184320004791/0001171843-20-004791-index.htm
2020-07-308-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1626971/000117184320005409/0001171843-20-005409-index.htm
2020-09-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1626971/000117184320006380/0001171843-20-006380-index.htm
2020-09-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1626971/000117184320006411/0001171843-20-006411-index.htm
2020-09-178-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1626971/000117184320006493/0001171843-20-006493-index.htm
2020-10-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1626971/000117184320007397/0001171843-20-007397-index.htm
2019-01-31SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1626971/000119312519023789/0001193125-19-023789-index.htm
2019-02-12SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1626971/000119312519035923/0001193125-19-035923-index.htm
2019-07-29SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1626971/000119312519205471/0001193125-19-205471-index.htm
2020-02-12SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1626971/000119312520033205/0001193125-20-033205-index.htm
2020-07-09SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1626971/000119312520190472/0001193125-20-190472-index.htm
2019-07-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626971/000120919119043285/0001209191-19-043285-index.htm
2020-05-063Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626971/000120919120027486/0001209191-20-027486-index.htm
2020-07-094Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626971/000120919120041990/0001209191-20-041990-index.htm
2018-08-0210-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1626971/000155837018006236/0001558370-18-006236-index.htm
2018-11-0110-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1626971/000155837018008268/0001558370-18-008268-index.htm
2019-03-0710-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1626971/000155837019001660/0001558370-19-001660-index.htm
2019-04-24DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1626971/000155837019003229/0001558370-19-003229-index.htm
2019-04-24DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1626971/000155837019003232/0001558370-19-003232-index.htm
2019-05-0910-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1626971/000155837019004697/0001558370-19-004697-index.htm
2019-08-0110-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1626971/000155837019006824/0001558370-19-006824-index.htm
2019-10-2910-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1626971/000155837019009354/0001558370-19-009354-index.htm
2020-03-0910-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1626971/000155837020002232/0001558370-20-002232-index.htm
2020-04-15DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1626971/000155837020003917/0001558370-20-003917-index.htm
2020-04-15DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1626971/000155837020003923/0001558370-20-003923-index.htm
2020-04-3010-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1626971/000155837020004797/0001558370-20-004797-index.htm
2020-07-3010-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1626971/000155837020008756/0001558370-20-008756-index.htm
2020-10-2910-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1626971/000155837020012039/0001558370-20-012039-index.htm
2019-06-104Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626971/000156761919013152/0001567619-19-013152-index.htm
2019-06-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626971/000156761919013222/0001567619-19-013222-index.htm
2019-11-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626971/000156761919021570/0001567619-19-021570-index.htm
2019-12-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626971/000156761919023137/0001567619-19-023137-index.htm
2019-12-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626971/000156761919023139/0001567619-19-023139-index.htm
2019-12-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626971/000156761919023140/0001567619-19-023140-index.htm
2019-12-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626971/000156761919023143/0001567619-19-023143-index.htm
2019-12-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626971/000156761919023146/0001567619-19-023146-index.htm
2019-12-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626971/000156761919023147/0001567619-19-023147-index.htm
2019-12-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626971/000156761919023148/0001567619-19-023148-index.htm
2020-03-234Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626971/000156761920006904/0001567619-20-006904-index.htm
2020-03-234Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626971/000156761920006905/0001567619-20-006905-index.htm
2020-03-234Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626971/000156761920006907/0001567619-20-006907-index.htm
2020-03-234Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626971/000156761920006908/0001567619-20-006908-index.htm
2020-03-234Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626971/000156761920006909/0001567619-20-006909-index.htm
2020-03-234Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626971/000156761920006910/0001567619-20-006910-index.htm
2020-06-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626971/000156761920012097/0001567619-20-012097-index.htm
2020-06-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626971/000156761920012098/0001567619-20-012098-index.htm
2020-06-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626971/000156761920012099/0001567619-20-012099-index.htm
2020-06-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626971/000156761920012100/0001567619-20-012100-index.htm
2020-06-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626971/000156761920012101/0001567619-20-012101-index.htm
2020-06-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626971/000156761920012102/0001567619-20-012102-index.htm
2020-09-153Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626971/000156761920016741/0001567619-20-016741-index.htm
2020-09-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626971/000156761920016744/0001567619-20-016744-index.htm
2020-03-19EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1626971/999999999520000598/9999999995-20-000598-index.htm

Corvus Pharmaceuticals, Inc (CRVS) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Corvus Pharmaceuticals, Inc (CRVS). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 498%
Institutional Ownership: 6375%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2018-12-20RICHARD A MD MILLERPresident and CEOBuy5,000.004.4022,000.001,103,795.00https://www.sec.gov/Archives/edgar/data/1626971/000089924318031696/0000899243-18-031696-index.htm
2018-12-20RICHARD A MD MILLERPresident and CEOBuy5,000.004.3921,950.001,108,795.00https://www.sec.gov/Archives/edgar/data/1626971/000089924318031696/0000899243-18-031696-index.htm
2018-12-04RICHARD A MD MILLERPresident and CEOBuy1,502.005.958,936.901,113,795.00https://www.sec.gov/Archives/edgar/data/1626971/000089924318030242/0000899243-18-030242-index.htm
2018-12-06RICHARD A MD MILLERPresident and CEOBuy5,000.005.9929,934.001,118,795.00https://www.sec.gov/Archives/edgar/data/1626971/000089924318030539/0000899243-18-030539-index.htm
2018-12-27RICHARD A MD MILLERPresident and CEOBuy20,000.003.2965,884.001,128,795.00https://www.sec.gov/Archives/edgar/data/1626971/000089924318031989/0000899243-18-031989-index.htm
2019-06-07RICHARD A MD MILLERPresident and CEOBuy9,212.003.3731,018.651,138,007.00https://www.sec.gov/Archives/edgar/data/1626971/000156761919013222/0001567619-19-013222-index.htm
2019-06-11RICHARD A MD MILLERPresident and CEOBuy6,000.003.6722,020.001,144,007.00https://www.sec.gov/Archives/edgar/data/1626971/000156761919013222/0001567619-19-013222-index.htm
2019-06-13RICHARD A MD MILLERPresident and CEOBuy343.003.521,207.361,144,350.00https://www.sec.gov/Archives/edgar/data/1626971/000089924319017182/0000899243-19-017182-index.htm
2019-06-14RICHARD A MD MILLERPresident and CEOBuy11,657.003.4039,666.441,156,007.00https://www.sec.gov/Archives/edgar/data/1626971/000089924319017182/0000899243-19-017182-index.htm
2019-08-06RICHARD A MD MILLERPresident and CEOBuy5,000.003.5817,875.001,161,007.00https://www.sec.gov/Archives/edgar/data/1626971/000089924319021352/0000899243-19-021352-index.htm
2019-08-07RICHARD A MD MILLERPresident and CEOBuy2,500.003.548,850.001,163,507.00https://www.sec.gov/Archives/edgar/data/1626971/000089924319021352/0000899243-19-021352-index.htm
2019-11-12RICHARD A MD MILLERPresident and CEOBuy272.002.90788.801,163,779.00https://www.sec.gov/Archives/edgar/data/1626971/000156761919021570/0001567619-19-021570-index.htm
2019-11-13RICHARD A MD MILLERPresident and CEOBuy14,736.003.0044,240.421,178,515.00https://www.sec.gov/Archives/edgar/data/1626971/000156761919021570/0001567619-19-021570-index.htm
2020-07-08Holdings A/S Novo10% Share HolderSell741,440.005.373,985,165.861,389,498.00https://www.sec.gov/Archives/edgar/data/1626971/000120919120041990/0001209191-20-041990-index.htm
2020-07-07Holdings A/S Novo10% Share HolderSell796,622.005.254,183,380.772,130,938.00https://www.sec.gov/Archives/edgar/data/1626971/000120919120041990/0001209191-20-041990-index.htm
2018-12-21LEIV LEAChief Financial OfficerBuy24,700.004.15102,408.6724,700.00https://www.sec.gov/Archives/edgar/data/1626971/000089924318031810/0000899243-18-031810-index.htm
2019-07-25Holdings A/S Novo10% Share HolderSell1,400,000.004.005,600,000.002,927,560.00https://www.sec.gov/Archives/edgar/data/1626971/000120919119043285/0001209191-19-043285-index.htm
2019-06-06LEIV LEAChief Financial OfficerBuy15,500.003.5655,180.0040,200.00https://www.sec.gov/Archives/edgar/data/1626971/000156761919013152/0001567619-19-013152-index.htm
2019-07-24Holdings A/S Novo10% Share HolderSell53,240.005.01266,711.104,327,560.00https://www.sec.gov/Archives/edgar/data/1626971/000120919119043285/0001209191-19-043285-index.htm
2019-07-23Holdings A/S Novo10% Share HolderSell39,716.005.32211,134.234,380,800.00https://www.sec.gov/Archives/edgar/data/1626971/000120919119043285/0001209191-19-043285-index.htm
2019-06-07LEIV LEAChief Financial OfficerBuy10,000.003.3833,800.0050,200.00https://www.sec.gov/Archives/edgar/data/1626971/000156761919013152/0001567619-19-013152-index.htm
2019-06-27ORBIMED ADVISORS LLCDirectorBuy32,923.003.34109,962.826,000,507.00https://www.sec.gov/Archives/edgar/data/1626971/000094787119000486/0000947871-19-000486-index.htm
2019-06-27Peter A. ThompsonDirectorBuy32,923.003.34109,962.826,000,507.00https://www.sec.gov/Archives/edgar/data/1626971/000094787119000487/0000947871-19-000487-index.htm
2019-06-28ORBIMED ADVISORS LLCDirectorBuy565,178.003.722,102,462.166,565,685.00https://www.sec.gov/Archives/edgar/data/1626971/000094787119000486/0000947871-19-000486-index.htm
2019-06-28Peter A. ThompsonDirectorBuy565,178.003.722,102,462.166,565,685.00https://www.sec.gov/Archives/edgar/data/1626971/000094787119000487/0000947871-19-000487-index.htm
2019-07-01ORBIMED ADVISORS LLCDirectorBuy59,243.003.91231,640.136,624,928.00https://www.sec.gov/Archives/edgar/data/1626971/000094787119000486/0000947871-19-000486-index.htm
2019-07-01Peter A. ThompsonDirectorBuy59,243.003.91231,640.136,624,928.00https://www.sec.gov/Archives/edgar/data/1626971/000094787119000487/0000947871-19-000487-index.htm
2019-08-06ORBIMED ADVISORS LLCDirectorBuy142,656.003.51500,722.566,767,584.00https://www.sec.gov/Archives/edgar/data/1626971/000094787119000571/0000947871-19-000571-index.htm
2019-08-06Peter A. ThompsonDirectorBuy142,656.003.51500,722.566,767,584.00https://www.sec.gov/Archives/edgar/data/1626971/000094787119000572/0000947871-19-000572-index.htm